Ensol Biosciences's revenue for the
six
months ended in Dec. 2023 was ₩176.5 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₩176.5 Mil.
Ensol Biosciences's Revenue per Share for the
six
months ended in Dec. 2023 was ₩16.46.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16.46.
Warning Sign:
Ensol Biosciences Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Ensol Biosciences was -81.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -37.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 10 years, Ensol Biosciences's highest 3-Year average Revenue per Share Growth Rate was 34.30% per year. The lowest was -37.60% per year. And the median was 1.80% per year.
Ensol Biosciences Revenue Historical Data
The historical data trend for Ensol Biosciences's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ensol Biosciences's Revenue
For the Biotechnology subindustry, Ensol Biosciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensol Biosciences's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensol Biosciences's Revenue distribution charts can be found below:
* The bar in red indicates where Ensol Biosciences's Revenue falls into.
Ensol Biosciences Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₩176.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Ensol Biosciences Revenue Related Terms
Thank you for viewing the detailed overview of Ensol Biosciences's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ensol Biosciences (XKRX:140610) Business Description
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:140610 has been successfully added to your 